-
1 Comment
Sirio Pharma Co., Ltd. is currently in a long term downtrend where the price is trading 20.0% below its 200 day moving average.
From a valuation standpoint, the stock is 10.2% cheaper than other stocks from the Consumer Defensive sector with a price to sales ratio of 6.1.
Sirio Pharma Co., Ltd. 's total revenue rose by 40.6% to $538M since the same quarter in the previous year.
Its net income has increased by 100.2% to $62M since the same quarter in the previous year.
Finally, its free cash flow grew by 7084.7% to $45M since the same quarter in the previous year.
Based on the above factors, Sirio Pharma Co., Ltd. gets an overall score of 4/5.
| Exchange | SHE |
|---|---|
| CurrencyCode | CNY |
| Industry | Packaged Foods |
| ISIN | CNE100003NB0 |
| Sector | Consumer Defensive |
| Dividend Yield | 4.5% |
|---|---|
| Target Price | 30.78 |
| Beta | 0.87 |
| Market Cap | 6B |
| PE Ratio | 18.34 |
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutraceutical gummies; probiotic products; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging. Sirio Pharma Co., Ltd. was founded in 1993 and is headquartered in Shantou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300791.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
